Bionano Genomics, Inc. cash flow to debt ratio of -236.37% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bionano Genomics, Inc.'s free cash flow has increased -76.32% from $-69.03M last year to $-16.34M, signaling increasing performance

Bionano Genomics, Inc.'s debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability.

Bionano Genomics, Inc.'s debt has decreased relative to shareholder equity from 0.77 last year to 0.21 today, signaling strengthened financials

Bionano Genomics, Inc. has a net cash position, so leverage is healthy.

Bionano Genomics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Bionano Genomics, Inc.'s profit margin has increased (-70.72%) in the last year from -363.98% to -106.58%, signaling increasing performance

Bionano Genomics, Inc.'s short-term assets of $45.39M exceed its short-term liabilities of $22.94M

Bionano Genomics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bionano Genomics, Inc.'s return on equity of -78.78%, is lower than 15.00%, indicating bad performance

Bionano Genomics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bionano Genomics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Bionano Genomics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Bionano Genomics, Inc. has negative free cash flow, indicating cash burn

Bionano Genomics, Inc.'s yearly earnings has increased -76.44% since last year from $-112.02M to $-26.39M, signaling increasing performance

Bionano Genomics, Inc.'s yearly revenue has decreased 7.37% since last year from $30.78M to $28.51M, signaling decreasing performance

ROIC -83.76% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bionano Genomics, Inc.'s 3-year revenue CAGR of 0.84% is positive, indicating growing revenue over the past 3 years

Bionano Genomics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Bionano Genomics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Bionano Genomics, Inc. has insufficient data to evaluate this check.

Bionano Genomics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bionano Genomics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Bionano Genomics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Bionano Genomics, Inc. is overvalued relative to its fair value price of -220.29 based on Earnings Fair Value model

Bionano Genomics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bionano Genomics, Inc. has a price-to-book ratio of 0.42x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bionano Genomics, Inc. has a price-to-sales ratio of 0.44x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue